Literature DB >> 11481135

Executive dysfunction and disability in elderly patients with major depression.

D N Kiosses1, S Klimstra, C Murphy, G S Alexopoulos.   

Abstract

The authors studied 126 elderly patients without dementia and with unipolar major depression. Impairment in instrumental activities of daily living (IADLs) was significantly associated with age (P<0.0001), gender (P<0.001), medical burden (P=0.013), severity of depression (P=0.01), initiation/perseveration (IP; P=0.035), and IP x depression (P=0.029). Depression was associated with IADL impairment mainly in patients with impaired IP. Among the cognitive impairments, IP-only contributed significantly to IADL impairment, whereas attention, construction, conceptualization, and memory did not. Attention to executive function and disability may guide clinical management and lead to development of innovative pharmacological and behavioral interventions.

Entities:  

Mesh:

Year:  2001        PMID: 11481135

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  33 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  A Meta-Analysis of Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression.

Authors:  Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed
Journal:  Am J Geriatr Psychiatry       Date:  2015-05-21       Impact factor: 4.105

3.  Association of age at depression onset with cognitive functioning in individuals with late-life depression and executive dysfunction.

Authors:  R Scott Mackin; J Craig Nelson; Kevin L Delucchi; Patrick J Raue; Derek D Satre; Dimitris N Kiosses; George S Alexopoulos; Patricia A Arean
Journal:  Am J Geriatr Psychiatry       Date:  2014-02-26       Impact factor: 4.105

4.  Attention/processing speed prospectively predicts social impairment 18 years later in mood disorders.

Authors:  Casey Sarapas; Stewart A Shankman; Martin Harrow; Robert N Faull
Journal:  J Nerv Ment Dis       Date:  2013-09       Impact factor: 2.254

5.  Physical frailty in late-life depression is associated with deficits in speed-dependent executive functions.

Authors:  Guy G Potter; Douglas R McQuoid; Heather E Whitson; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-27       Impact factor: 3.485

6.  Association of attentional shift and reversal learning to functional deficits in geriatric depression.

Authors:  Guy G Potter; Douglas R McQuoid; Martha E Payne; Warren D Taylor; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2012-01-24       Impact factor: 3.485

7.  The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults.

Authors:  Lauren A Rog; Lovingly Quitania Park; Danielle J Harvey; Chun-Jung Huang; Scott Mackin; Sarah Tomaszewski Farias
Journal:  Clin Neuropsychol       Date:  2014-02-06       Impact factor: 3.535

Review 8.  Pharmacological treatment of depression in older patients with chronic obstructive pulmonary disease: impact on the course of the disease and health outcomes.

Authors:  A M Yohannes; G S Alexopoulos
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

9.  A bayesian approach to examining default mode network functional connectivity and cognitive performance in major depressive disorder.

Authors:  Rui Wang; Kimberly M Albert; Warren D Taylor; Brian D Boyd; Justin Blaber; Ilwoo Lyu; Bennett A Landman; Jennifer Vega; Sepideh Shokouhi; Hakmook Kang
Journal:  Psychiatry Res Neuroimaging       Date:  2020-05-17       Impact factor: 2.376

Review 10.  A model for intervention research in late-life depression.

Authors:  George S Alexopoulos; Martha L Bruce
Journal:  Int J Geriatr Psychiatry       Date:  2009-12       Impact factor: 3.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.